NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT00483561 2023-09-13
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
University of Nebraska
Phase 2 Terminated
NCT00025116 2020-04-06
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Canadian Cancer Trials Group
Phase 2 Completed
NCT00014183 2019-11-07
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
University of Maryland, Baltimore
Phase 2 Completed
NCT00467077 2017-03-17
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
California Cancer Consortium
Phase 2 Terminated
NCT00479089 2015-11-02
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00012337 2013-06-24
ZD 1839 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00265070 2013-02-05
Trial of Iressa in Prostate Cancer Patients
AstraZeneca
Phase 2 Completed
NCT00014144 2012-10-08
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
SWOG Cancer Research Network
Phase 2 Completed
NCT00242918 2012-02-07
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
Benaroya Research Institute
Phase 2 Completed
NCT00319787 2011-01-25
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
AstraZeneca
Phase 2 Completed
NCT00241475 2009-04-23
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
AstraZeneca
Phase 2 Completed
NCT00635856 2009-04-23
Open Label Trial to Assess Iressa in Prostate Cancer Patients
AstraZeneca
Phase 2 Completed
NCT00246974 2008-10-15
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
AstraZeneca
Phase 2 Completed